CompletedNot applicableNCT00407602
Argus® II Retinal Stimulation System Feasibility Protocol
Studying Retinitis pigmentosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Second Sight Medical Products
- Principal Investigator
- Anne-Marie RipleySecond Sight Medical Products
- Intervention
- Implant of Argus II Retinal Prosthesis(device)
- Enrollment
- 30 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2019
Study locations (12)
- Doheny Eye Institute, Los Angeles, California, United States
- University of California San Francisco, San Francisco, California, United States
- Johns Hopkins, Wilmer Eye Institute, Baltimore, Maryland, United States
- Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute, New York, New York, United States
- University of Pennsylvania, Scheie Eye Institute, Philadelphia, Pennsylvania, United States
- Wills Eye Hospital, Philadelphia, Pennsylvania, United States
- Retina Foundation of the Southwest, Dallas, Texas, United States
- Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12, Paris, France
- Puerta de Hierro, Centro Medico, Centro de Retina, Zapopan, Jalisco, Mexico
- Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205, Geneva, Switzerland
- Moorfields Eye Hospital, Vitreoretinal Research Unit, London, United Kingdom
- Manchester Royal Eye Hospital, Manchester, United Kingdom
Collaborators
National Eye Institute (NEI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00407602 on ClinicalTrials.govOther trials for Retinitis pigmentosa
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGNANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNANCT07292987Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPHASE2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics
- RECRUITINGPHASE2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)jCyte, Inc